Células - tronco e Derivados
Os inibidores de células-tronco são compostos que visam especificamente as vias de sinalização e proteínas envolvidas na manutenção, diferenciação e proliferação de células-tronco. Esses inibidores são cruciais para compreender a biologia das células-tronco e para desenvolver estratégias para manipular células-tronco para fins terapêuticos, como medicina regenerativa e tratamento do câncer. Ao controlar o destino das células-tronco, esses inibidores podem ajudar a orientar a diferenciação das células-tronco em tipos celulares específicos ou prevenir o crescimento celular indesejado. Na CymitQuimica, oferecemos uma seleção de inibidores de células-tronco de alta qualidade para apoiar sua pesquisa em biologia de células-tronco, biologia do desenvolvimento e medicina regenerativa.
Subcategorias de "Células - tronco e Derivados"
- Gama-secretase(59 produtos)
- Hedgehog/Smoothened(44 produtos)
- Via Hippo(6 produtos)
- JAK(245 produtos)
- Porcupine(9 produtos)
- ROCK(70 produtos)
- STAT(98 produtos)
- Células - tronco(486 produtos)
- TGF-beta/Smad(58 produtos)
- Wnt/beta-catenina(66 produtos)
Exibir 2 mais subcategorias
Foram encontrados 695 produtos de "Células - tronco e Derivados"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
LX-7101 hydrochloride
CAS:<p>LX-7101 hydrochloride is a potent LIMK and ROCK2 inhibitor with antihypertensive activity, inhibits LIMK1/2, ROCK, PKA, and can be used to study glaucoma.</p>Fórmula:C23H29N7O3xHClPureza:98.96%Cor e Forma:SolidPeso molecular:487.99ABC99
CAS:<p>ABC99 irreversibly inhibits wnt-deacylating enzyme NOTUM (IC50: 13 nM) with high serine hydrolase family selectivity.</p>Fórmula:C22H21ClN4O5Pureza:99.89%Cor e Forma:SoildPeso molecular:456.88Cirevetmab
CAS:<p>Cirevetmab (ZTS-00521426), a caninized monoclonal antibody targeting Canis lupus familiaris TGFB1, is classified as an immunoglobulin G2-kappa.</p>Cor e Forma:Liquidγ-Secretase modulator 10
CAS:<p>γ-Secretase modulator 10 is a novel γ-secretase modulator.</p>Fórmula:C25H23F3N4O2Cor e Forma:SolidPeso molecular:468.48AS2553627
CAS:<p>AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.</p>Fórmula:C18H19N5OCor e Forma:SolidPeso molecular:321.38HC-258
CAS:<p>HC-258 is a direct TEAD inhibitor covalent Cys380, and reduces the transcriptional levels and inhibits the migration of CTGF, CYR61, AXL and NF2 MDA-MB-231.</p>Fórmula:C20H24N2O2Cor e Forma:SolidPeso molecular:324.42JAK2-IN-10
CAS:<p>JAK2-IN-10 (compound 5) is a potent inhibitor of JAK2v617f, with an IC50 value of ≤10 nM.</p>Fórmula:C33H33D3FN9O2Cor e Forma:SolidPeso molecular:612.71Casein kinase 1δ-IN-6
CAS:<p>CK1δ-IN-6: potent, selective CK-1δ inhibitor, IC50 23 nM, neuroprotective, anti-inflammatory, for neurodegenerative research.</p>Fórmula:C16H10ClF3N2OSPureza:99%Cor e Forma:SoildPeso molecular:370.78JAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Fórmula:C22H23FN4O3SCor e Forma:SolidPeso molecular:442.51Povorcitinib phosphate
CAS:<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>Fórmula:C23H25F5N7O5PPureza:99.57%Cor e Forma:SolidPeso molecular:605.45JAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Fórmula:C18H20F3N7OCor e Forma:SolidPeso molecular:407.401WAY-656935
CAS:<p>WAY-656935 inhibits ROCK.</p>Fórmula:C20H28ClN3O3SPureza:98.1%Cor e Forma:SolidPeso molecular:425.97GSK3-IN-1
CAS:<p>GSK3-IN-1 is a GSK3B-glycogen synthase kinase-3 beta inhibitor.</p>Fórmula:C14H10ClN3OSPureza:99.66%Cor e Forma:SolidPeso molecular:303.77TEAD-IN-19
<p>TEAD-IN-19 (Compound 1l) is a transcriptional inhibitor of TEAD, showing inhibition rates of 38.5%, 36.2%, 57.8%, and 71.3% for TEAD1, TEAD2, TEAD3, and TEAD4, respectively, at 10 μM. It exhibits strong antiproliferative and antimigratory effects on prostate cancer cell lines and significantly reduces the expression of TEAD-regulated downstream genes. TEAD-IN-19 holds potential for research in the field of cancer therapeutics.</p>Cor e Forma:Odour SolidPROTAC YAP degrader-1
<p>PROTAC YAP degrader-1, a targeted proteolysis promoting chimeric molecule, both degrades the YAP protein and inhibits its nuclear localization. This compound is formulated with Demethyl-NSC682769 as the target protein ligand, and utilizes (R,S,R)-AHPC-PEG2-C2-boc, which is the E3 ubiquitin ligase ligand + Linker conjugate. The linker incorporated in the design is Acid-PEG2-C2-Boc.</p>Fórmula:C56H62N6O9SCor e Forma:SolidPeso molecular:995.19RBPJ Inhibitor-1
CAS:<p>RBPJ Inhibitor-1 (RIN1), a compound that impedes the functional interaction between RBPJ and SHARP, effectively inhibits NOTCH-dependent tumor cell</p>Fórmula:C17H14FN3O2Pureza:99.58%Cor e Forma:SoildPeso molecular:311.31S-Ruxolitinib
CAS:<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Fórmula:C17H18N6Pureza:98%Cor e Forma:SolidPeso molecular:306.37SJ10542
CAS:<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Fórmula:C41H46N12O5SCor e Forma:SolidPeso molecular:818.95FRM-024
CAS:<p>FRM-024 is a powerful gamma secretase modulator with the ability to penetrate the central nervous system (CNS), designed specifically for the treatment of</p>Fórmula:C22H22ClN5O2Cor e Forma:SolidPeso molecular:423.9CIA-1 (Free base)
CAS:<p>CIA-1, a COUP-TFII inhibitor, has IC50 of 1.2-7.6 μM in prostate cancer cells; inhibits tumor growth in mouse prostate cancer.</p>Fórmula:C17H19N3O2SPureza:99%Cor e Forma:SolidPeso molecular:329.42WDR5 ligand 2
CAS:<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Fórmula:C29H31F3N4O4Cor e Forma:SolidPeso molecular:556.576Notch 1 TFA
<p>Notch 1 TFA encodes a member of the NOTCH family of proteins.</p>Fórmula:C64H98N15F3O25S3Pureza:98%Cor e Forma:SolidPeso molecular:1614.81Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS:<p>Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.</p>Fórmula:C88H138N20O34P2Pureza:98%Cor e Forma:SolidPeso molecular:2082.1Fasudil
CAS:<p>Fasudil (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.</p>Fórmula:C14H17N3O2SPureza:99.79% - 99.84%Cor e Forma:SolidPeso molecular:291.37JAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Cor e Forma:Odour SolidSJ1008030 formic
<p>SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an</p>Fórmula:C43H45N13O9SPureza:98%Cor e Forma:SolidPeso molecular:919.96TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Fórmula:C23H21FN4O2Cor e Forma:SolidPeso molecular:404.16485Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Fórmula:C63H107N19O20S2Pureza:98%Cor e Forma:SolidPeso molecular:1514.77Wnt/β-catenin agonist 3
CAS:<p>Wnt/β-catenin agonist 3 is a Wnt/beta-catenin agonist.</p>Fórmula:C16H15ClN4O2Pureza:99.52%Cor e Forma:SolidPeso molecular:330.77Sotatercept
CAS:<p>Sotatercept (ACE-011) is an ActRIIA-Fc fusion protein and an inhibitor of activin signaling.</p>Pureza:97% (SDS-PAGE); 97.8% (SEC-HPLC) - 97% (SDS-PAGE); 97.8% (SEC-HPLC)Cor e Forma:LiquidTYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Cor e Forma:Odour SolidSJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Fórmula:C36H36N10O5Cor e Forma:SolidPeso molecular:688.74JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Fórmula:C30H33FN4O3SCor e Forma:SolidPeso molecular:548.67YAP-IN-1
<p>YAP-IN-1 (Compound (+)-1) is an autophagy inhibitor specifically targeting YAP1. It binds to the Hippo pathway transcription factor YAP1 with a Kd of 9.13 μM, promoting its degradation through the chaperone-mediated autophagy (CMA) pathway. This process inhibits the Rab7-mediated fusion of autophagosomes with lysosomes and decreases autophagy levels without affecting lysosomal function. YAP-IN-1 shows potential for cancer research, including in hepatocellular carcinoma and breast cancer.</p>Cor e Forma:Odour SolidCBT-295
<p>CBT-295, an orally active autotaxin (ATX) inhibitor, effectively decreases inflammatory cytokines including TGF-β, TNF-α, and IL-6, along with the bile duct proliferation marker CK-19, and ameliorates liver fibrosis. The compound's ability to reverse liver fibrosis contributes to lowered ammonia levels in the blood and brain, which in turn reduces ammonia-induced neuroinflammation. CBT-295 shows potential for the study of liver cirrhosis and related encephalopathy.</p>Fórmula:C18H20ClN3OCor e Forma:SolidPeso molecular:329.82P17 Peptide
CAS:<p>P17 Peptide, a human TGF-β1 inhibitory peptide, effectively blocks the activity of woodchuck TGF-β1.</p>Fórmula:C95H139N27O21Cor e Forma:SolidPeso molecular:1995.29WAY-297174
CAS:<p>WAY-297174 is a human protein kinase CK2 inhibitor with IC50 of > 33 μM.</p>Fórmula:C11H12N2O2S2Pureza:99.53%Cor e Forma:SoildPeso molecular:268.36STAT3-IN-31
<p>STAT3-IN-31 (compound K2071), derived from STATtic, acts as an inhibitor of both STAT3 and mitotic processes. This compound interrupts mitotic progression and impacts the formation of the mitotic spindle. Additionally, STAT3-IN-31 hampers migration in glioblastoma cells, suppresses cellular proliferation within tumor spheroids, induces senescence in glioblastoma, and inhibits the growth of Temozolomide-resistant cells while reducing the secretion of the pro-inflammatory cytokine monocyte chemoattractant protein (MCP-1).</p>Fórmula:C16H15NO3SCor e Forma:SolidPeso molecular:301.36SJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Fórmula:C42H43N13O7SCor e Forma:SolidPeso molecular:873.94STAT3-IN-34
<p>STAT3-IN-34 (Compound 15E) acts as a STAT3 inhibitor, blocking both the nuclear translocation and the transcriptional regulator activity of STAT3. It effectively inhibits HaCaT cell proliferation with an IC50 value of 0.008 μM. Additionally, STAT3-IN-34 reduces IL-17A expression and mitigates Imiquimod-induced psoriasis in mouse models.</p>Fórmula:C19H16N2O4SCor e Forma:SolidPeso molecular:368.41Epigenetics Compound Library
<p>Well-chosen 953 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new</p>Cor e Forma:Odour SolidGSK-3β inhibitor 19
<p>GSK-3β Inhibitor 19 (compound 36) is an inhibitor of GSK-3β with an IC50 value of 70 nM. It is applicable in research related to anti-inflammatory and Alzheimer's disease.</p>Fórmula:C15H12N4O2SCor e Forma:SolidPeso molecular:312.355β-Cholanic acid
CAS:<p>5β-Cholanic acid (5beta-Cholanic acid) is a potent γ-secretase modulator used in Alzheimer's disease research.</p>Fórmula:C24H40O2Pureza:98.91% - 99.89%Cor e Forma:SoildPeso molecular:360.57ROCK2-IN-9
<p>ROCK2-IN-9 (compound 7u), a selective ROCK2 inhibitor with an IC50 value of 36.8 nM, demonstrates anticancer properties by impeding cancer cell migration and invasion. This action is achieved through the regulation of various actin cytoskeleton cellular activities. It holds potential for use in breast cancer research.</p>Fórmula:C28H30N8O2Cor e Forma:SolidPeso molecular:510.59Ripasudil free base
CAS:<p>Ripasudil free base (K-115 (free base)) is a selective and potent ROCK inhibitor, is a novel and potent antiglaucoma agent.</p>Fórmula:C15H18FN3O2SPureza:98%Cor e Forma:SolidPeso molecular:323.39Wnt/Hedgehog/Notch Compound Library
<p>A unique collection of 237 Wnt/Hedgehog/Notch signaling targeted compounds for high throughput and high content screening;</p>Cor e Forma:Odour SolidFDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Cor e Forma:LiquidPSEN1-IN-2
<p>PSEN1-IN-2 (Compound 13K) is a potent inhibitor of both PSEN1-APH1A and PSEN1-APH1B complexes, exhibiting IC50 values of 6.9 nM and 2.4 nM, respectively.</p>Fórmula:C20H18ClFN2O3SCor e Forma:SolidPeso molecular:420.88NIBR-LTSi
<p>NIBR-LTSi is a selective LATS kinase inhibitor that also activates YAP signaling, promotes tissue stem cell expansion and tissue regeneration in vitro/vivo.</p>Fórmula:C18H20N4OPureza:99.87%Cor e Forma:SolidPeso molecular:308.38Fresolimumab
CAS:<p>Fresolimumab (GC1008) is a human monoclonal antibody targeting active TGFβ1, TGFβ2, TGFβ3, studied for cancer and focal segmental glomerulosclerosis.</p>Pureza:> 95% - > 95%Cor e Forma:LiquidPeso molecular:144.4 kDa
